Importantly, in contrast to the available IPF treatments, pirfenidone and nintedanib, which are not able to induce disease remission neither in patients nor in preclinical mouse models (Inomata et al., 2014; Oku et al., 2008; Tanaka et al., 2012), we show here that AAV9-Tert therapy effectively accelerates the regression of pulmonary fibrosis in mice. Here, TERT is linked to pulmonary fibrosis.